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Natural Killer Cells: Research Shows
They Are Early Destroyers of Malignancy
Natural killer (NK) cells, whose name comes from their natural ability
to destroy tumor cells quickly without deliberate immunization or clonal
expansion, are cytotoxic lymphocytes that originate in bone marrow
and are present primarily in peripheral blood and lymphoid tissues.
Because they may offer important protection against malignancy, Eva
Lotzov~, PhD, professor of immunology and chief of the MDAH Laboratory of lmmunogenetics in the Department of General Surgery, is
investigating how to induce or augment them to increase an individual's immunity to cancer.
These cytotoxic lymphocytes deviate from T cells, B cells, and
macrophages phenotypically and functionally. They are capable of
rapidly killing a wide range of primary and metastatic tumors, both
fresh and cultured.
In an interview, Lotzova explained why she believes NK cells, rather
than T cells or macrophages, are the first line of defense against malignancy. "NK cells seem to be more important as a first defense because,
to mediate anti tumor immunity, macrophages need nonspecific stimulation, and T cells, after contact with tumors, must proliferate and form
specific tumor-directed clones. This takes several days to a week," she
said.
"In addition, T cell surveillance capability is limited because these
cells react primarily to tumors that express strong tumor-specific antigens, and these tumors are quite rare. In contrast, NK cells do not
require priming, react within 30 minutes to a few hours, and recognize tumors that do not express strong tumor-associated antigens. This
argues for a vital role of NK cells in the surveillance system."
To understand how NK cells function, Lotzova stressed that these
cells must be seen in the context of the total immune system because
their function can be influenced, positively and negatively, by the system's other components. It is known, for instance, that various cell
populations produce such biologically active substances as interferon
and interleukin-2, which stimulate NK cells.
In 1977 Lotzova and her coworkers were the first to find that NK
cells are also regulated negatively by suppressor cells. NK cell-directed
suppressor cells were in most systems characterized as macrophages,
though T cetls were also shown to suppress NK cell actiUTI'.u-. - -Lotzova believes that the early appearance ofNK cells in phylogenetic
development and their preservation in higher species, including
humans, affirms their basic biologic role as a mechanism of natural
immunity. NK cells appear in primitive invertebrates, in whom malignant transformation is rare. This phylogenetic heritage may explain
why NK cells perform a basic defense role in recognizing "non-self"
structures, defending the host against microbial, viral, parasitic, and
fungal infections. Furthermore, in primitive invertebrates as well as
in humans, NK cells appear to regulate the growth and differentiation
of hemopoietic and lymphoid tissues. Homeostatic regulation and maintenance of the integrity of the organism may be the intrinsic biologic

function ofNK cells, according to Lotzova, and may precede their function as defenders against malignant disease.
Morphologically, NK cells are easily identified by a high cytoplasmto-nucleus ratio, an indented to kidney-shaped nucleus, and azurophilic
granules in their cytoplasm. Because of these characteristics, NK cells
acquired the designation of large granular lymphocytes (LGLs)
{Fig. 1). Even though LGLs have been known for more than 40 years,
their cytotoxic powers have been recognized only in the last decade,
according to Lotzova. Most NK cells seem to be LGLs, but not all LGLs
are necessarily active NK cells.

Absence or Suppression of NK Cells
Just as the NK cells' presence indicates continuing immunosurveillance, their absence or aberrance indicates a weakening of antitumor
immunity. Patients with Chediak-Higashi syndrome, an autosomal
recessive disorder, have a high susceptibility to neoplasia, and their
LGLs have a morphological defect: a single large cytoplasmic granule
replaces the multiple small azurophilic granules present in the normal
LGL. This finding of an association between NK cell morphological
characteristic and functional defect underscores the importance of
recognizing the clues NK cell morphology may offer to diagnosis of
clinical immunodeficiency.
Other conditions linked to NK cell deficiency and susceptibility to
neoplasia are X-linked lymphoproliferative syndrome, combined
immunodeficiency syndrome, systemic lupus erythematosus, paroxysmal nocturnal hemoglobinuria, Sjogren's syndrome, various types of
leukemia, and immunodeficiency in allogeneic kidney graft recipients.
Suppression of NK cells also translates into a weakening of anti tumor
immunity. Experimental animals treated with antibodies directed
continued on fxlge 2
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Fig. 1. Large granular lymphocytes have a high cytoplasm-to-nucleus
ratio, an indented nucleus, and azurophillic granules in the cytoplasm.
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continued from page 1
against NK cells (asialo GM-1 and NK 1.1 antibody) displayed a higher
incidence of tumors and lower clearance of tumor cells upon tumor
transplantation in vivo. A similar phenomenon was observed by Lotzova's group and other investigators in infant mice that lack active NK
cells. Furthermore, such carcinogens as urethane and dimethylbenzanthracene and such tumor promoters as phorbol ester and teleocidin
suppress NK cell function and seem to contribute to tumor induction
by these agents.

NK Cell Resistance to and Therapy for Leukemia
Lotzova's studies of patients who had acute and chronic myeloid
leukemia showed that some had a low frequency of LGLs and others
had normal numbers but defects in NK cell lytic mechanisms. These
defects included low NK cell cytotoxicity, a low rate of target cell
lysis, inability to generate NK cell cytotoxic factor (NKCF), impaired
ability to bind to tumors, and virtually no recycling (or renewed
capacity) to lyse tumors.
In these patients NK cells were killing, at most, one tumor cell each,
whereas normal NK cells kill up to seven tumor cells each. The observation that patients with preleukemic disorders have a similar deficiency in NK cell activity suggests that defective NK cell levels or
performance are primary to leukemia. In other words, leukemia seems
to be a consequence of low NK cell activity rather than the cause.
Leukemia begins in the bone marrow, the site of NK cell origin. Lotzova suggests that once the bone marrow is disturbed, as is the case
in patients with preleukemic disorders, NK cell production, differentiation, and influx to blood and other tissues are affected and
immunosurveillance is weakened.
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"In the light of the NK cells' antileukemic effect," Lotzova said,
" we asked whether the NK cell cytotoxic impairment could be
corrected in vitro under interleukin-2 stimulation, and we found that
NK cell lytic activity was restored within 6 to 21 days in culture. These
data demonstrated that the NK cell defect of leukemic patients is a
transitory phenomenon, and that the NK cells' tumor-directed cytotoxic potential can be repaired in culture. This strongly suggested that
propagation of autologous NK cells of leukemia patients in vitro and
their reinfusion in patients may represent a new therapeutic approach
to the treatment of leukemia.''
Lotzova and a member of her laboratory, C . A . Savary, PhD,
currently clone and propagate NK cells from leukemic patients and
normal donors to investigate the cells' antitumor potential. The goal
is future NK cell therapy for patients with leukemia (Fig. 2).
Lotzova's research provides strong evidence for the role of NK cells
in resistance to human leukemia. "The objection to cancer-related
laboratory findings," Lotzova said, "has often been that the reactivity
of the effector cells-NK cells, T cells, or macrophages-was frequently evaluated against cultured tumors, and such reactivity may not
realistically reflect antitumor activity against fresh tumor cells.
"To test whether NK cells were active against fresh human leukemic
cells, we used the clonogenic leukemic cell assay, and we were able
to show that inhibition of fresh leukemic stem cells was manifested
by both allogeneic and autologous NK cells. Our studies, some of them
done in collaboration with members of the Division of Medicine,
demonstrated that NK cells display resistance against fresh clonogenic leukemic cells-leukemic stem cells-the population of leukemic cells
that may be most relevant for expansion of leukemia in vivo," she said.
In other experiments, Lotzova's group studied the cell surface phenotype ofNK cells involved in the antileukemic effect using the chronic
myelogenous leukemia model and monoclonal antibodies directed
against NK cells (Leu-11 and Leu-7) and T cells (Leu-1).
"These studies demonstrated that the leukemia inhibitory activity
was abrogated after treatment with Leu-11, and partially with Leu-7
antibody, but not by treatment with Leu-1 antibody, which indicated
again that NK cells are involved in this phenomenon," she said.
Studies of the .mechanism of NK cell-mediated inhibition of clonogenic leukemic cells showed, furthermore , that NKCF is at least
partially responsible for the leukemia-inhibitory effect.

NK Cells and Solid Cancer Therapy

Because of the NK cells' ability to fight tumors, scientists have
Editor
searched for ways to enhance the cells' antitumor effect. Lotzova and
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Fig. 2. Three NK cells from a normal donor attack the K-562 cell line,
which was derived from a patient with chronic myeloid leukemia in
blast crisis. Note multiple granules evident in the NK cells' cytoplasm.

Fig. 3. Two natural killer cells bind to ovarian cells.

After studies with the pyrimidinones in mice indicated that regional potentiation of NK cytotoxicity was paralleled by regression of growth
of mammary adenocarcinoma, Lotzova's group, in collaboration with
Ralph Freedman, MD, Department of Gynecology, and James M.
Bowen, PhD, vice president for academic affairs and professor of virology
in the Department of Tumor Biology, turned to studying the NK cytotoxic profile of ovarian cancer patients before and after intraperitoneal
injection of viral oncolysates {extracts derived from allogeneic cultured
ovarian tumor cells whose surface membranes have been modified by
the PR-8-A-34 strain of influenza virus) {Fig. 3).
According to Lotzova, ovarian cancer is an excellent model for
investigating antitumor immunity in general, because it allows study
of the tumor's immunologic profile in situ. Studies of NK cell cytotoxic activity in the peritoneal fluids of ovarian cancer patients showed
that the levels of NK cell cytotoxicity were very low, ranging from
0 to 15%. After treatment; NK cell cytotoxicity increased up to 80%,
and the NK cell potentiating effect lasted three to four weeks {Fig.
4). The research revealed that the functional NK cell activity in
ovarian cancer patients was paralleled by an increase in LGL numbers
in the peritoneal fluids and, most important, that the potentiation of
NK cell cytotoxic potential was reflected by the regression of malignant ascites. These were completely eradicated in two patients and
reduced by 58% to 87% in the other four.

coworkers recently investigated the effect of two new interferoninducing pyrimidinone molecules-2-amino-5-bromo-6-phenyl,4-pyrimidinol (ABPP) and 2-amino-5-iodo-7-phenyl.+pyrimidinol (AIPP) on
NK cell and anti tumor activity. A single intraperitoneal injection of
the pyrimidinones (250 mg/kg) resulted in strong induction of NK cell
activity in peritoneal exudate, lungs, and liver {tissue expressing low
or no NK cell activity) and consistent augmentation of NK cell cytotoxicity against various tumors in the spleen, bone marrow, and peripheral blood of several strains of mice.
"These results are encouraging because they indicate that regional
administration of these agents results not only in regional but also in
systemic NK cell augmentation. Especially important may be the potentiation of NK cell activity in liver and lungs, the tissues of frequent
tumor metastasis. Augmenting NK cells at these sites may diminish
metastatic potential," Lotzova said.
In the next series of experiments, Lotzova and her group used B6D2F 1
hybrid mice to investigate whether NK cell potentiation by AIPP would
affect the growth of regionally injected mammary adenocarcinoma
ascitic tumor (ACA-755) of B6 origin. Mice were treated with AIPP
before or after the tumor cell injection. Omtrol mice invariably died
within 17 days. The AIPP-treated mice, however, survived more than
continued on fxlge 7
four months after the tumor inoculation without any signs of tumor
growth.
To determine whether the effect was truly due to the potentiation
,-,----, ,-2----, ,-a--, r-•-i r-•--,
r-•---,
of NK cells, Lotzova and coworkers treated AIPP-injected mice with
01 : 12 ]
NK 1.1 antiserum {which abrogates NK cell activity), with Thy 1.2
e t :2 S
T:E CELL RATIO
a 1:so
1: 100
antibody (to rule out a T cell effect), and with normal mouse serum
as a control. All mice were injected with ACA-755 tumor. Mice that
received no AIPP treatment died. All mice treated with AIPP, AIPP
arrd 11onnahnouse serum, or AIPhnd antv"fhyt-hm:tboduy--..ru...--,,t.,,,,-i---- -+-- - --<>--., . ---..1--- ---1J.hL--- ----11-+9-- ----'-=,,___ __J___
the tumor challenge. Most of the mice treated with AIPP and the NK
cell antibody NK 1.1 died from the tumor.
"This experiment showed without any doubt," Lotzova explained,
"that once you stimulate NK cell antitumor immunity and then
NUMBER OF INJECTIONS OF VIRAL ONCOLYSATES
abrogate the NK cells' action, you no longer have the protective
effect. Because the pyrimidinones are powerful stimulators of NK cell
Fig. 4. Injecting viral oncolysates intraperitoneally raised NK cell
activity, they may be particularly important in cancer therapy. Curcytotoxicity from pretreatment levels (P) of 0-15% to as high as 80%
in six patients with ovarian cancer. Tumor cell-to-effector cell (T:E)
rently, it appears that regional administration of these agents may tum
ratios varied from 1: 12 to 1: 100.
out to be most efficient in cancer therapy."
■
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Better Classification and New Drug Regimens
Have Advanced Treattnent for Lymphoid Cancer
Table 1. A Working Formulation
of Non-Hodgkin's Lymphomas for Clinical
Use and Equivalents in Rappaport Classification

Fernando F. Cabanillas, MD, Department of Hematology, Section of
Lymphoma, Division of Medicine, The University of Texas M. D.
Anderson Hospital and Tumor Institute at Houston

Working Formulation

Our ability to classify, diagnose, and treat patients who have a
variety of lymphomas has advanced much in recent years. Work in
cytogenetics is beginning to clarify the origin of these tumors, and
immunobiological research has helped us to understand their behavior.
In 1982, an international panel of hematopathologists brought together
by the National Cancer Institute proposed a rational classification
system of lymphomas. With parallel advances in chemotherapy, we
can now treat and cure many patients who have aggressive lymphoid
disorders.

Classification
The new working formulation. By the time the nomenclature for
lymphoma, devised by Henry Rappaport in 1956 and published by the
U.S. Armed Forces Institute of Pathology ih 1966, became accepted
in our country, it was scientifically obsolete. The main problem was
the term "histiocytic lymphoma," which suggested that these tumors
were derived from histiocytes. Immunologic studies had already proved
that these neoplasms arise from lymphocytes.
The intervening decade brought scores of new classification proposals,
all arousing confusion, skepticism, and controversy. As a result, the
National Cancer Institute sponsored a multi-institutional study that
gave us a new system of nomenclature called the "International Working Formulation." The system blends the salient aspects of previous
classifications, such as Rappaport's and Lennert's, and it organizes
lymphomas into three histological _grades according to tumor aggressiveness and the patients' long-term prognosis. The Working Formulation provides a common language for clinicians and pathologists in
different countries and institutions. The new classification with its
equivalents in the Rappaport system is shown in Table 1.
New pathological entities. The recognition of two possibly related new
entities, peripheral T cell lymphoma and adult T cell lymphoma/leukemia, illustrates the rapid development of this field, thanks mainly to
immunologic methods like the use of cell surface markers, which make
it possible to distinguish tumors of B cell from those of T cell origin.
The main clinical characteristics of peripheral T cell lymphoma are
advanced stage at presentation; frequent "B" symptoms; elevated
lactic dehydrogenase (LOH) levels; in varying percentages of patients,
involvement of lung or pleura, spleen, or marrow; polyclonal hyperglobulinemia or hypoglobulinemia; and such autoimmune conditions
as hemolytic anemia.
Peripheral T cell lymphomas can be subclassified histologically
according to lymphoma cell size as diffuse small cell, diffuse mixed,
or diffuse large cell lymphomas. In the past, because of histological
and clinical similarities, many of these neoplasms were confused with
Hodgkin's disease, angioimmunoblastic lymphadenopathy, and
immunoblastic sarcoma. The diffuse small cell variant of peripheral
T cell lymphoma has been known as Lennert's lymphoma.
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Low Grade
A. Malignant lymphoma
Small lymphocytic
consistent with chronic

Rappaport Equivalents
Diffuse well-differentiated
lymphocytic lymphoma

lymphocytic leukemia,

plasmacytoid
B. Malignant lymphoma, follicular Nodular poorly
Predominantly small cleaved
differentiated
cell-diffuse areas of sclerosis lymphocytic
C. Malignant lymphoma, follicular
Mixed, small cleaved and
large cell-diffuse areas
of sclerosis

Intermediate Grade
D. Malignant lymphoma, follicular
Predominantly large cell -diffuse areas of sclerosis

Nodular mixed

Nodular large cell

E. Malignant lymphoma, diffuse
Small cleaved cell-sclerosis

Diffuse poorly
differentiated
lymphocytic

F. Malignant lymphoma, diffuse
Mixed, small and large
cell-sclerosis, epithelioid
cell component
G. Malignant lymphoma, diffuse
Large cell-cleaved cell,
noncleaved cell, sclerosis

Diffuse mixed

High Grade
H. Malignant lymphoma
Large cell, immunoblastic-plasmacytoid,
clear cell, polymorphous,
epithelioid cell
component
I.

Malignant lymphoma
Lymphoblastic -convoluted
cell, nonconvoluted cell

J. Malignant lymphoma

Diffuse large cell

Diffuse large cell

Diffuse poorly
differentiated
lymphocytic
(lymphoblastic)

Diffuse undifferentiated

Small noncleaved cell Burkitt' s, follicular areas

Miscellaneous
Composite
Mycosis fungoides
Histiocytic
Extramedullary plasmacytoma
Unclassifiable
Other
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Table 3. Common Karyotypic Abnormalities in B Cell Lymphomas

Cell Type

Variants

Common
t(8;14)

(q24;q32)

t(8;22)
t(2;8)

(q24;q11)
(p13;q24)

t(14;18)

(q32;q21)

t(7;14)
t(8;14)

(q23;q32)
(q22;q32)

t(8;14)
t(14;18)
+3

(q24;q32)
(q32;q21 l
+10

Burkitt's

Follicular
("nodular")
Diffuse large
cell

del (6)
+7
+12

(q21)

Fernando F. Cabanillas
Today some pathologists believe that most, perhaps all, cases of
angioimmunoblastic lymphadenopathy actually represent cases of
peripheral T cell lymphoma. Therapy for these disorders has not been
highly curative, and it remains to be seen if more modem chemotherapy
regimens can extend these patients' survival for longer than the
current median of about one year.
Adult T cell leukemia/lymphoma, first described in Japan where the
disorder is widespread, represents the other newly identified lymphadenopathic disease. The neoplasm has been linked to the recently
described human T cell leukemia virus and appears to be caused by it.
The virus was recovered from cultured tumor cells, and its discovery
offers hope of identifying other viruses that may cause lymphomas in
humans.

transplantation, an intervention still too risky to be used except as
a last resort.

Chromosomal Abnormalities
The introduction of the banding technique in cytogenetics has made
it clear that many chromosomal abnormalities in leukemia and lymphoma are consistent and not random. Some of these abnormalities
are translocations, and deletions and extra chromosomes also occur
frequently. Table 3 is a summary of the common karyotypic abnormalities of these lymphomas. Much knowledge remains to be gained
in distinguishing, or classifying correctly, the correlations of chromosomal abnormality and lymphoma type.

Management
Prognostic Factors
Knowledge of pertinent prognostic factors is crucial for planning clinical trials as well as analyzing their results. Several studies of prognostic factors of these heterogeneous tumors have been conducted in the
past 10 years. The results of these studies have been similar, although
some differences are evident from the summary shown in Table 2. Most
of the data are derived from patients with aggressive lymphomas. Some
differences arose from the use of different treatment regimens and some
from the inclusion of different histological tumor types. Basically, the
presence of bulky tumor and elevation of LDH level predict a poorer
response. Identifying patients who have these adverse characteristics
may lead to innovative therapeutic approaches such as bone marrow

Stages I and II aggressive lymphomas. Although most patients with
lymphoma present with advanced stage III or IV disease, some present
with earlier-stage disease. Considerable controversy exists about the
best therapy for these patients, particularly for those whose tumors are
classified in the Working Formulation as intermediate and high-grade
aggressive. Whether surgical staging is necessary and whether
chemotherapy alone, radiotherapy alone, or a combination of the two
offers the best results have been the central questions.
One complication is that the median age of patients with
lymphoma other than Hodgk.in's disease is 55 years. Consequently,
elective surgical staging is often contraindicated in at least a third of
continued on page 7

Table 2. Major Prognostic Factors That Predict Complete Response in Lymphoma
Marrow

Investigators* Treatment

Diagnosis

Bulkiness

LOH

Involvement
+

Koziner

CTX-L2 & NHL-3

OHL

NA

++

Cabanillas
Fisher

COP

ALL

NA

CVP, CMOPP,
BACOP,XRT
CHOP-BLEO

OHL, DUL

++
++

OHL

++

++

Velasquez

+

Prior
Rx

+
+

B

Age

Sex

Symptom:>

+
+

++

++
NA

++

Abbreviations: CTX-L 2, cyclophosphamide-L 2; NHL-3, non-Hodgkin's lymphoma stage 3; OHL, diffuse histiocytic
_ _ _ _ _ __,_,Irrnghoma· NA. not analyzed: COP cyclophosphamide. vincristine (Oncovinl prednisone: ALL acute lymphoblastic leukemia·
CVP, cyclophosphamide, vincristine, prednisone; CMOPP, cyclophosphamide, methotrexate, Oncovin, procarbazine,
prednisone; DUL, diffuse undifferentiated lymphoma; BACOP, bleomycin, doxorubicin (Adriamycin), cyclophosphamide,
Oncovin, prednisone; XRT, X-ray therapy; CHOP-BLEO, cyclophosphamide, doxorubicin, Oncovin, prednisone, bleomycin.
*Investigators: Kozineretal., Cancer49:1571-1579, 1982; Cabanillasetal.,Arch. Intern. Med. 138:413-418, 1978;
Fisher et al., Blood 58:45-51, 1981; Velasquez et al., Proceedings of the American Society of Clinical Oncology 3:244,
1984, abstract C-954.
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Rural Science Park is Laboratory
for Basic Work on Carcinogenesis
Describing the fundamental investigations at the UT System Cancer
Center's Science Park,Research Division at Smithville as ''research
in cancer cause and prevention" is accurate, but it's a summary, not
an explanation.
Earlier this year, the 200,page grant application reviewing the divi,
sion's research activities resulted in a $1 million five,year award from
the American Cancer Society. As a result of the large grant, the
researchers will now be able to conduct studies of the influence of nutri,
tion and dietary habits on the etiology of neoplastic diseases, in addi,
tion to enlarging the staff and buying some costly laboratory equipment.
The goal of more than 100 staff members in the "think tank"
environment in Bastrop County is to advance understanding of the
three basic processes of cancer: cell damage, change, and proliferation
as a result of genetic or environmental influences. Closest neighbors
to benefit from this knowledge will be the clinicians and patients at
UT MDAH but, obviously, the benefits will be worldwide.
Research at Science Park, directed by Thomas J. Slaga, PhD, and
associate director Earl F. Walborg, PhD, is supported by many other
grants and nonstate funds totaling slightly more than $3 million per
year and by state funds of nearly $1 million a year.

"We are rapidly becoming one of the premier carcinogenesis research
centers in the world," Slaga said.

Cancer Causation
Currently, studies of the causes of cancer include investigations of
the critical cellular and molecular targets of chemically induced
carcinogenesis in several models, including the skin, vagina, liver, and
tracheobronchial tree of rodents. The researchers are attempting to
clarify carcinogenic stages and to identify the cellular processes in tumor
formation.
Because one biological consequence of DNA damage is malignant
disease, the scientists are analyzing DNA changes that occur when
animals or cells in culture are exposed to carcinogenic agents. Cell
survival and mutation are being studied, as are the reactions of cells
known to have good or poor DNA repair capacity.
Although the viral origin of thyroid tumors in leukemic mice is
known, the role of viral chromosomal sequences in chemical, or
radiation,i~duced formation of lymphomas remains to be determined.
Science Park researchers are using lymphoma,prone mice to study the
role of recombinational genetic events and altered viral proteins in
leukemia in these animals.
Work with hybrid fish is yielding information about the role of specific
gene loci of a heritable melanoma, and a study of the normal growth
and differentiation of stem cells-embryonic cells in skin, blood, and
other systems-is intended to reveal early carcinogenic events during
the evolution of these cells.

Preventing Cancer Induction
Animal tumor models-mouse skin, rat liver, rat respiratory system,
and mouse vagina-are providing Science Park researchers with infor,
mation about the inhibition of cancer formation. If nontoxic
inhibitors-such as antioxidants, some vitamins, protease and poly,
amine inhibitors, selenium, interferon, steroids, and hormonelike
compounds-prove active in some of the models tested, the work may
lead to a rational approach to cancer prevention in human beings .
The study of skin cancer prevention shows, for example, that some
of these nontoxic compounds inhibit formation of skin tumors at dif,
ferent stages of cell development. It may be possible, therefore, to coun,

Wooded path in Science Park.
Thomas J. Slaga
6
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teract carcinogenesis with very low doses of a combination of antioxidants, protease inhibitors, and an inhibitor of the enzyme omithine
decarboxylase, difluoromethylomithine (DFMO).
Interferon, DFMO, and antioxidants in various combinations seem
to inhibit mutagenesis and carcinogenesis in mouse skin and liver.
Selenium and beta-carotene may prove to be tumor inhibitors in a
model that employs allogeneic mouse liver transplants. Hormonal compounds, because of their relation to oral contraceptives, are being tested
for both tumor induction and tumor inhibition in mouse vagina, and
the possible halting of morphogenesis and tumor progression of bronchial carcinoma is studied in in vitro as well as in vivo models that
include transplanted tissue.
The influence of dietary life-style and nutrition on cancer is next
on the Science P~rk program because many studies have shown that
nutrients and other dietary components may alter the incidence of
tumors in a variety of epithelial tissues, including skin, lung, bladder,
breast, pancreas, colon, and liver.
This new program, funded by the American Cancer Society, will
focus on the mechanisms by which dietary fat contributes to cancer
induction in the mammary gland, large bowel, or pancreas.
"The new project," Slaga said, "will add a new dimension to our
research activities as well as advance our current work."
Science Park researchers come from many different disciplines, and
they collaborate with scientists at UT MDAH, The University of Texas
at Austin, and Texas A&M University. They contribute to undergraduate training at nearby Southwest Texas State University at San
Marcos, Southwestern University at Georgetown, and Trinity University at San Antonio. Graduate fellows come from UT-Austin, Texas
A &M, and the Graduate School of Biomedical Sciences of the UT
Health Science Center at Houston. lOncoLogl
(Physicians who desire more information may write Thomas]. Slaga, PhD,
director, Science Park-Research Division, The University of Texas System
Cancer Center, P.O . Box 389, Smithville, Texas 78957-ED.)

Natural Killer
continued from page 3
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To be certain that the anti tumor effect was caused by NK cells, Lotzova and her associates used NK cell-specific Leu-11 antibody and complement to treat the effector cell population. This treatment abolished
NK cell activity directed against malignant ascites in both normal
donors and ovarian cancer patients and confirmed theNK cells' role
in reactivity to these types of tumors. In addition, •Lotzova demonstrated
that incubating malignant ascites with NK cells resulted in production of NKCF, which on its own (without NK cells) was effective in
killing malignant ovarian cells. The studies with ovarian cancer
patients thus showed that NK cell potentiation or adoptive transfer
of NK cells or NKCF may represent a viable therapy for ovarian cancer.

Applications
"I do not believe that I am overly optimistic in suggesting that the
information on NK cells, which we and other investigators are providing, could result in vital therapy for certain patients with leukemia,
ovarian cancer, and perhaps also with other types of malignancies,"
Lotzova said. She believes that cloning propagation of NK cells in vitro
may lead to new protocols for cancer treatment, and that such treatVol. 30, No. 3

ments as NK cell transfusion or infusion of NKCF will be a part of
NK cell protocols in future therapies.
"We can propagate NK cells in vitro. They grow well and retain
their cytotoxic function for several months, which indicates that this
approach is technically feasible. Animal experimental studies have
demonstrated that such in vitro cloned NK cells are effective in mediating tumor resistance," she said.
NK cells also have been shown to be effective in fighting infections,
she said, so that further work should allow potentiation of the
antimicrobial resistance of patients receiving chemotherapy. In addition, Lotzova and others have shown that NK cells are involved in
rejection of allogeneic bone marrow transplants. NK cells may therefore have prognostic value in the selection of donor-recipient pairs for
bone marrow transplantation. PncoI.ogJ
(Physicians who desire addi.tiorud information may write Eva Lotzovii, PhD,
Laboratory of Immunogenetics, Department of General Surgery, MDAH
Box 41, The University of Texas M. D. Anderson Hospital and Tumor
Institute, 6723 Bertner Avenue, Houston, Texas 77030-ED.)

Better Classification
continued from page 5
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these patients, either because of age or associated medical problems.
Furthermore, these aggressive tumors may progress in a short time. Up
to 20% of patients in some series have developed progressive disease
either soon after surgical intervention or during radiotherapy. That
is why we believe it is better to use clinical rather than surgical staging, but this also means that we will fail to identify a small percentage of
patients who have subclinical stages III or IV disease.
We and others have used combination chemotherapy that resulted
in an 80% to 86% relapse-free survival of patients at two years and
80% to 100% overall survival at two years. These data have to be
interpreted carefully, however, because patients with early-stage
aggressive lymphomas seem to be more prone to late relapse than
patients with more advanced lymphomas. Usually, however, second
remissions are relatively easy to attain in cases of late relapse.
Our current policy is to use clinical staging followed immediately
by chemotherapy with doxorubicin-based regimens, followed by radiotherapy later to consolidate treatment gains. The role of radiotherapy
is still not totally clear, but it is likely to help prevent local relapse,
especially in patients who have bulky tumors. Use of clinical staging
followed only by radiotherapy has been abandoned by most investigators because of poor results.
Stages III and IV aggressive lymphomas. The single most important
factor in predicting whether or not patients with lymphoma can be
cured is the quality of their therapeutic response , Complete response
(CR) becomes progressively difficult for patients at higher lymphoma
stages.
The first effective treatments for patients with aggressive lymphomas were limited by the small number of active drugs available. Thus,
if a patient achieved only a partial remission after being treated with
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),
not much else co~ld be done.
Two recently introduced regimens have consisted of such new drugs
as ifosfamide and etoposide (VP-16-213), as well as high-dose methocontinued on page 8
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continued from page 7
trexate. Using sequential chemotherapy regimens and late intensifi,
cation, we have been able to achieve a complete response in 46 of
56 patients who have aggressive lymphomas. Our CR rate for patients
with disease in stages I through III was 100%, and 66% for those in
stage IV. We schedule the treatment regimens according to response to
therapy, changing to the next regimen whenever a patient achieves
a less than complete response after three courses of CHOP. The next
regimen is doxorubicin, cytarabine, prednisone, and bleomycin (HOAP,
BLEO), and the next is ifosfamide, methotrexate, and etoposide
(IMVP, 16). Compared with previous experience with doxorubicin,based
chemotherapy, the multiregimen approach not only yields a higher
CR rate but also results in longer survival.
Refractory ar recurrent lymphomas. In our trials and those of others,
several single agents have shown activity in patients with recurrent
lymphomas, including etoposide (21 % response rate in 116 patients),
ifosfamide (47% in 15 patients), mitoguazone (37% in 63 patients},
and amsacrine (14% in 50 patients). In our most recent trial we used
mitoguazone, ifosfamide, methotrexate, and etoposide in a combina,
tion regimen called MIME. The analysis of the results of this regimen
is based on a regression model that predicts response rate based on
these pretreatment prognostic factors: quality of the patient's response
to first,line therapy, diagnosis (indolent versus agressive lymphoma),
and central nervous system involvement.
Among 208 patients treated with MIME, the overall response rate
was 60%, and the CR rate was 24%. Patients with aggressive lympho,
mas had a somewhat higher response rate: 64% overall and 32% CR.
Patients with indolent lymphomas in this group had a 54% overall
response rate and 12 % CR.
When we applied the regression model prospectively to the MIME,
treated patients, we found an overall expected response rate of 53%,
compared with the observed response rate of 60%, a significant differ,
ence. Major improvements occurred mainly in patients who had
indolent lymphomas and whose predicted probability of response was
lowest. We believe their improvement may be attributed to the inclu,
sion of mitoguazone, a drug with substantial activity in these tumor
types.
The median relapse,free survival of 15 months for the complete
responders to MIME has been identical to previous experience with
IMVP,16 and the amsacrine, ifosfamide, etoposide combination. About
20% to 30% of complete responders have maintained their response
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beyond two years, which suggests that they may be cured of lymphoma.
Other approaches to management of patients with recurrent
lymphomas include megadose chemotherapy with or without radio,
therapy and rescue by either autologous or allogeneic marrow trans,
plantation. From one study, it appears that Burkitt's lymphoma is
especially amenable to autologous bone marrow transplantation
because of the tumor's sensitivity to alkylating agents. The hetero,
geneity of the lymphomas and the limited experience with bone
marrow transplantation make interpretation of these studies difficult.
Further work with combined chemotherapy regimens and bone
marrow transplantation will have to be done. But, meanwhile, the
classification of the lymphomas has made treatment trials both more
logical and successful, and it has improved our ability to evaluate our
own and others' attempts to treat and cure these patients. IOncoL:,g!
(Physicians who desire additional information may write Fernando F.

Cabanillas, MD, Department of Hematology, MDAH Box 77, The
University of Texas M. D. Anderson Hospital and. Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 7703~ED.)

New Book: Candidiasis
Candidias~, edited by Gerald P. Bodey, Sr, MD, and Victor Fain,
stein, MD, both of the Department of Internal Medicine, Section of
Infectious Diseases, reviews current understanding of the pathogene,
sis, manifestations, diagnosis, treatment, and prevention of superficial
and systemic candida infections.
Published by Raven Press (1985, $45.50, 281 pages, 54 illustrations),
the book has 23 contributors from medical centers throughout the coun,
try, whose research and treatment reports emphasize candida infec,
tions in cancer and acquired immune deficiency syndrome patients and
in patients whose host defense mechanisms have been altered by
therapy. Therapies discussed include those with broad,spectrum
antibiotics, adrenal corticosteroids, cancer chemotherapeutic agents,
immunosuppressants used in organ transplantation, and intravenous
hyperalimentation.
Because the number of immunocompromised patients continues to
increase, Candidiasis will be of special interest to infectious disease
specialists, immunologists, and other clinicians who treat patients at
risk for candida infections. IOncol.ogj
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